RxDoctor Payments Data

Alexandra McMurray, MD

Child & Adolescent Psychiatry · Madison, WINPI 1942246749

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 29 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by AbbVie at 43.6% of the total. Reporting peaked in 2019 at $244 and has fallen 73.8% since, to $64 in 2025.

$537in general payments, 2019–2025

Across 29 payments — averaging $18.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$234
  • Sunovion Pharmaceuticals Inc.$161
  • Johnson & Johnson$50
  • Neuronetics, Inc.$31
  • Livanova USA, Inc.$22
  • Bausch Health US, LLC$14
  • plus $26 from 2 others

What the payments were for

  • Food & beverage$537100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$537 in reported general payments places this provider in the 80th percentile of 49 child & adolescent psychiatry providers in Wisconsin.

See all child & adolescent psychiatry providers in Wisconsin

Medicare billing

Part B allowed, 2024
$146,302
Medicare patients
121
Services billed
1,548

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl29$49,753
Seroquel XrQuetiapine Fumarate13$28,464
CaplytaLumateperone Tosylate13$21,961
TrintellixVortioxetine Hydrobromide39$18,671
RexultiBrexpiprazole13$18,454
VyvanseLisdexamfetamine Dimesylate15$5,491
Bupropion XlBupropion Hcl128$4,076
Temazepam13$3,823
Olanzapine126$3,318
Lurasidone Hcl36$2,988
Duloxetine Hcl125$2,977
Clozapine53$2,314
Ziprasidone Hcl21$2,278
Buspirone Hcl127$1,967
Lamotrigine129$1,946

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$234$49,75329 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse$13$24,16254 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 49 child & adolescent psychiatry providers in Wisconsin.

Other child & adolescent psychiatry in Madison

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →